Showing results (81-90 of 104) with videos related to
Sort By:
Pageof 11
Clinical Immunology (Orlando, Fla.)|August 14, 2016
Eosinophil peroxidase activates cells by HER2 receptor engagement and β1-integrin clustering with downstream MAPK cell signalingKerrie Hennigan, Paul J Conroy, Marie-Therese Walsh, et al.The Journal of Investigative Dermatology|December 31, 2010
Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infectionsJohn S Cho, Jamie Zussman, Niles P Donegan, et al.Clinical Immunology (Orlando, Fla.)|March 23, 2013
Eosinophil recruitment to nasal nerves after allergen challenge in allergic rhinitisMargaret A Thornton, Nadim Akasheh, Marie-Therese Walsh, et al.The Journal of Allergy and Clinical Immunology|September 21, 2020
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trialFlorence Roufosse, Jean-Emmanuel Kahn, Marc E Rothenberg, et al.Journal of Pediatric Gastroenterology and Nutrition|June 23, 2011
Exploring potential noninvasive biomarkers in eosinophilic esophagitis in childrenGirish Subbarao, Marc B Rosenman, Lyo Ohnuki, et al.Gastroenterology|April 29, 2014
Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitisBridget K Butz, Ting Wen, Gerald J Gleich, et al.The Journal of Allergy and Clinical Immunology|December 23, 2018
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitisJonathan Steinfeld, Eric S Bradford, Judith Brown, et al.The New England Journal of Medicine|May 18, 2017
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Praveen Akuthota, David Jayne, et al.The New England Journal of Medicine|March 18, 2008
Treatment of patients with the hypereosinophilic syndrome with mepolizumabMarc E Rothenberg, Amy D Klion, Florence E Roufosse, et al.The Journal of Allergy and Clinical Immunology|October 9, 2012
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromesFlorence E Roufosse, Jean-Emmanuel Kahn, Gerald J Gleich, et al.Pageof 11